53results about How to "Reduce the risk of side effects" patented technology

The invention discloses a chimeric T cell receptor STAR (Synthetic T Cell Receptor and Antigen Receptor), related preparations and drugs, and application of the chimeric T cell receptor STAR in preparation of cell drugs, and also relates to the preparation or an drug composition used for treatment of corresponding diseases such as tumors or infectious diseases.

The invention relates to 2,5-diaryl-1,3,4-oxadiazole compounds and a preparation method and application thereof. The preparation method comprises the following steps of: condensing benzoic acid of which a 4- site is replaced by R<1> and a 3- site is replaced by R<2> and which is taken as a raw material and m-Nitrobenzoylhydrazine in dichloromethane or tetrahydrofuran to obtain diacylhydrazine i; performing intramolecular dehydration cyclization on the diacylhydrazine i in acetonitrile by taking phosphorus oxychloride as a dehydration reagent to obtain an intermediate ii containing an oxadiazole ring; hydrogenating the intermediate ii under normal pressure under the catalysis of raney nickel to reduce a nitro group to obtain an amino substance iii; and finally, condensing the amino substance iii and acetic anhydride or 3,4-dimethoxyphenylacetic acid under the action of an acid-binding agent to obtain the 2,5-diaryl-1,3,4-oxadiazole compounds I. The invention also discloses application of the 2,5-diaryl-1,3,4-oxadiazole compounds I to the preparation of a medicine for treating type 2 diabetes mellitus.

The invention provides a dural/spinal dural biological patch material, a preparation method and application thereof. The obtained biological patch material is especially suitable for repair of dural/spinal dural defect, can maintain stable and non-degradable within 6 months-2 years after being implanted into the human body or animals, and can degrade gradually after more than 2 years. While ensuring certain mechanical properties and liquid seepage resistance, the biological patch material also has biocompatibility, has greatly reduced risks of postoperative complications and side effects, and meets the special requirements for dural/spinal dural defect repair materials.

The invention discloses an amidophenyl-1,3,4-oxadiazole compound shown in the formula (I). The invention also discloses a preparation method of the amidophenyl-1,3,4-oxadiazole compound. The preparation method comprises that an amino-compound II and a substituted aliphatic acid III are condensed to form the amidophenyl-1,3,4-oxadiazole compound. The invention also discloses a use of the amidophenyl-1,3,4-oxadiazole compound I in preparation of a drug for treating type II diabetes. The amidophenyl-1,3,4-oxadiazole compound has a non-AMP structure type, can reduce side-effect risk, can obviously inhibit FBPase in a molecule level, can substantially inhibit glucose generation in a cell level, and has good cell viability and good druggability.

The invention provides a preparation method of dezocine injection. The preparation method comprises the following steps: selecting water for injection as the solvent, adding with lactic acid, carrying out stirring for dissolving, and carrying out heating till the temperature is 35-50 DEG C; adding with the medicine, namely, dezocine, and carrying out stirring for clarification; adjusting the pH by adopting sodium hydroxide; and enabling the obtained solution to pass through carbon, carrying out filling, and carrying out high-temperature sterilization, thus obtaining the dezocine injection. For the dezocine injection prepared by adopting the method provided by the invention, the related substance of the medicine is not increased during the preparation process of the injection, meanwhile, three auxiliary materials, namely, sodium pyrosulfite, propylene glycol and sodium chloride are correspondingly reduced, and thus the stability of the injection is further enhanced; moreover, the variety of the used auxiliary materials is reduced, so that the risks generated due to the side effects of clinical medication are reduced, and the preparation method is suitable for the large-scale industrial production.

The invention discloses a novel liver-soothing Qi-regulating pill, which consists of twenty-one medicinal materials such as Chinese gentian and rhizoma cyperi. The pill is characterized by removing talc on the basis of the prior preparation process and retaining the prior medicinal efficacy. The invention also discloses a preparation method and application of the novel liver-soothing Qi-regulating pill.

Provided are an anti-human NGF antibody which is reduced in the influence on fetuses and the risk of adverse side effects including thrombosis while keeping a high neutralizing activity, and which has excellent safety, or an antigen-binding fragment thereof; and a means, utilizing the antibody or an antigen-binding fragment thereof , for preventing or treating various diseases for which human NGF is involved in the development of a disease state. An Fab' fragment of an anti-human NGF antibody comprises a heavy-chain variable region comprising the amino acid sequence represented by SEQ ID NO: 6 and a light-chain variable region comprising the amino acid sequence represented by SEQ ID NO: 4.

The invention relates to a medicinal composition, which particularly consists of a first agent of an antiviral medicament and a second agent of an immunomodulator, wherein the first agent, which is prepared by blocking virus messenger ribose nucleic acid (mRNA) translation and inhibiting the synthesis of virus nucleic acid in a cell. The medicinal composition can be used for treating organic pathological changes caused by enterovirus infections, such as a hand, foot and mouth disease.

The invention relates to a piercing-like device (10) for feeding a drug, for example into the penis for the purpose of treating erectile dysfunctions, comprising an elongate hollow body (12) having a first longitudinal end (14) and a second longitudinal end (16), wherein the hollow body (12) comprises a radially outer peripheral wall (18), which surrounds a radially inner, elongate hollow body (20). The peripheral wall (18) of the hollow body (12) has at least one drug outlet opening (22) between the two longitudinal ends (14, 16).

The invention discloses a pharmaceutical composition with a synergistic anti-melanoma effect and an application of the pharmaceutical composition, and the pharmaceutical composition comprises cinnamylaldehyde and dacarbazin. The composition disclosed by the invention has a relatively good melanoma resisting effect; the pathological experiments combined with the use of related mouse transplanted tumor models in the research of tumor pathogenesis find that cinnamaldehyde and dacarbazin are combined to achieve a strong effect of inhibiting the growth of solid tumors, and cinnamaldehyde and dacarbazin have a synergistic effect, so that the dosage of dacarbazin can be reduced, the risk of side effects caused by chemotherapeutics is reduced, and the pharmaceutical composition is applied to treatment of melanoma.

The invention relates to the pharmaceutical industry, in particular to a preparation method of a drug intermediate, and specifically discloses a preparation method of a precursor of ibrutinib. The preparation method comprises the following steps: (1) reacting a compound (III) with triphenylphosphine and azodicarbonic acid diester to obtain an intermediate (III-B); (2) reacting the intermediate (III-B) with a compound (IV) under the action of a catalyst to obtain an intermediate (V-C); and (3) reacting the intermediate (V-C) under the action of hydrochloric acid to obtain (R)-3-(4-phenoxy phenyl)-1-(piperidine-3-yl)-1H-pyrazolo [3, 4-d] pyrimidine-4-amine (I). The method has the advantages of high yield, high purity, convenience in purification, simplicity and convenience in operation and the like, is suitable for industrial production, and contributes to reducing the cost to a certain extent.

The invention provides an artemisia apiacea essential oil pet deodorization antibacterial liquid and a preparation method thereof. The artemisia apiacea essential oil pet deodorization antibacterial liquid comprises the following components in percentage by weight: 5-15% of artemisia apiacea essential oil, 5-10% of a deodorant, 3-8% of an antibacterial agent and the balance of water, the method comprises the following steps: firstly, collecting an artemisia apiacea stock solution, taking artemisia apiacea leaves, cutting the artemisia apiacea leaves into small pieces, putting the small pieces into a leaf mashing chamber, fully mashing, adding ethanol, stirring, extruding and filtering to obtain the artemisia apiacea stock solution, and flowing into a refining chamber; refining the artemisia apiacea stock solution: adding water into the artemisia apiacea stock solution in the refining chamber, heating and stirring, precipitating for 5-10 minutes after stirring completely, and obtaining supernatant through a suction guide pipe to obtain artemisia apiacea essential oil; and adding a deodorant, an antibacterial agent and water into the prepared artemisia apiacea essential oil in proportion, and fully stirring to obtain the pet deodorization antibacterial liquid containing the artemisia apiacea essential oil.

The invention relates to the technical field of biology, in particular to a low-immunogenicity anti-TNF-alpha humanized monoclonal antibody TCX063 and an application thereof. The anti-TNF-alpha humanized monoclonal antibody TCX063 having reduced immunogenicity, provided by the invention is obtained by modifying an FR region of an Infliximab monoclonal antibody. The antibody provided by the invention has the same TNF-alpha antigen binding site as that of the Infliximab monoclonal antibody, and retains the antigen affinity and specificity of the Infliximab monoclonal antibody, but the immunogenicity is obviously lower than that of the Infliximab monoclonal antibody. The low-immunogenicity TNF-alpha antibody can reduce the risk of drug side effects caused by immune response caused by antibodyimmunogenicity original nature in a human body. The antibody drug ADA is reduced. The in-vivo half-life period of the antibody is prolonged. Besides, a subcutaneous administration mode becomes possible, and great application potential and value are achieved.

The invention belongs to the technical field of medical instruments, and particularly relates to a surgical protective device which comprises an upper-layer pad, an upper-layer opening supporting ring, an upper-layer connecting strip, a lower-layer pad, a lower-layer opening supporting ring and a lower-layer connecting seat. Openings are formed in the upper-layer pad and the lower-layer pad, the positions of the openings of the upper-layer pad and the lower-layer pad are opposite, the upper-layer opening supporting ring is detachably connected to the opening of the upper-layer pad, the upper end of the upper-layer connecting strip is installed on the upper-layer opening supporting ring, and the lower-layer opening supporting ring is detachably connected to the opening of the lower-layer pad. The lower end of the lower layer connecting base is fixedly installed on the lower layer opening supporting ring and detachably connected with the lower end of the upper layer connecting strip, and at least two ropes are further arranged at the lower end of the lower layer opening supporting ring. The lower-layer opening supporting ring and the upper-layer opening supporting ring are positioned through the upper-layer connecting strip, the lower-layer connecting base and the rope, so that the protection effect is achieved, and the trouble that a protection pad needs to be fixed manually in the whole operation process is reduced.

The invention relates to the fields of immunological technology, biotechnology and biological medicine, in particular to a polypeptide for preventing novel coronavirus pneumonia COVID-19, an immunogenic conjugate and application of the polypeptide and the immunogenic conjugate. The immunogenic conjugate comprises a polypeptide with an amino acid sequence as shown in SEQ ID NO.1, and is used for preparing a vaccine for preventing COVID-19. The immunogenic conjugate is a synthetic peptide vaccine prepared by synthesizing a target polypeptide based on a known or predicted section of antigen epitope amino acid sequence in a pathogen antigen gene, combining the synthesized target polypeptide with a carrier protein to prepare a polypeptide conjugate, and adding an adjuvant. Compared with a traditional attenuated vaccine, an inactivated vaccine and other novel vaccines, the vaccine can quickly cope with virus variation; the field requirement for vaccine production is reduced, and large-scale batch production is easy to realize; the research and development cost and the research and development period are reduced; safety, no toxicity and stability are realized; as the molecular structure is small and simple, the problems of serious complications and iatrogenic infection are rarely caused.

The invention relates to the technical field of biology, in particular to an anti-TNF-alpha humanized monoclonal antibody TCX060 having low immunogenicity and low ADCC/CDC function and an applicationof the anti-TNF-alpha humanized monoclonal antibody TCX060. The anti-TNF-alpha humanized monoclonal antibody TCX060 provided by the invention is obtained by modifying a cetuzumab monoclonal antibody as follows: (1) removing PEG modifications; (2) performing transforming into a humanized IgG1 subtype full-length antibody; and (3) inserting a flexible amino acid fragment between a CDR3 region and aCH2 region. The binding affinity of the TCX060 and humanized TNF alpha is close to that of cetuzumab, binding of the TNF alpha and a cell surface TNF receptor can be specifically blocked, the ADCC/CDCfunction of the TCX060 is close to that of the PEG cetuzumab monoclonal antibody, the immunogenicity of the TCX060 is obviously lower than that of the cetuzumab monoclonal antibody, the risk that theantibody generates immunogenicity in bodies is reduced while removing the ADCC/CDC function, and excellent application value can be achieved.

The invention relates to the fields of immunological technology, biotechnology and biological medicine, in particular to a vaccine for preventing novel coronavirus pneumonia COVID-19 and a preparation method thereof. A composition of immunogenic conjugates includes at least two combinations of immunogenic conjugates containing the same carrier protein or at least two combinations of immunogenic conjugates containing two different carrier proteins. The composition of the immunogenic conjugates is used for preparing a vaccine for preventing COVID-19. Compared with a traditional attenuated vaccine, an inactivated vaccine and other novel vaccines, the vaccine can quickly cope with virus variation; the field requirement for vaccine production is reduced, and large-scale batch production is easy to realize; the research and development cost and the research and development period are reduced; safety, no toxicity and stability are realized; as the molecular structure is small and simple, the problems of serious complications and iatrogenic infection are rarely caused.